CONTACT US: 1.800.301.5033


Decentralized Clinical Trials: A New Approach to Infectious Disease Clinical Trials

The ongoing struggle to control SARS-CoV-2 highlights the need for rapidly deployed antiviral drugs and vaccines. Speed of development is a primary advantage, as ready availability and deployment of effective vaccines and therapies has a direct impact on the magnitude of epidemics and pandemics.

In this article on page 29 in the August 2021 issue of International Clinical Trials, Clinical Ink Chief Strategy Officer Jonathan Andrus discusses how a decentralized approach, using a platform that captures data directly into the digital record, gives clinical trial sponsors the flexibility and speed needed to race ahead of the competition and get necessary treatments to patients worldwide.

Download and Read This Resource Now

Screen Shot 2021-08-12 at 1.08.33 PM